The global T-Cell
Therapy Market size is expected
to reach USD 7.51 billion, expanding at a CAGR of 15.4% by 2026, according to a
new report by Grand View Research, Inc. The landmark approvals of Yescarta and
Kymriah have spurred unprecedented advancements in the market. The launch of
these breakthrough therapies has bolstered cash inflow for innovation, thereby
driving the growth.
Expansion of the market for
T-cell therapy significantly relies on shifting preference from first-line stem
cell transplants and chemotherapy to third-line CAR T-cell therapy. Moreover,
the ever-expanding plethora of medical conditions for which the T cell
therapies is projected to bode well for the market growth. Rise in oncological
disorders is projected to drive interest as well as investments in the T-cell
therapy market in near future.
In contrast with the
small-molecule landscape, engineered T cells market landscape is distinguished
by an extensive network that encompasses several entities marked by connections
academically, financially, and via technology licensing. Research bodies, and
manufacturers, and regulators engage in assessing the long-term efficacy and
safety of therapies to ensure safe access to patients.
By far, the antigen challenge
and linked toxicity concerns have impeded the development of CAR T therapies in
non-hematological malignancies. Market players are applying a data-driven
approach of exploring this space to mitigate the challenge and expand the usage
of T-cell therapy in indication type such as brain cancer and melanoma.
Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/t-cell-therapy-market
https://www.grandviewresearch.com/industry-analysis/t-cell-therapy-market
Further key
findings from the report suggest:
- In the coming years, the number of hospitals
implementing CAR T therapies is expected to increase, thereby driving the
commercialized business model
- Research-based business modality accounted for the
highest revenue generation over the past years, attributed to the presence
of several research programs
- CAR-T cell therapy market share accounted for the larger
revenue share of the overall T-cell therapy market in 2018 owing to the
highest investment by sponsors in this therapy type
- Presence of approved products for B cell lymphoma and
acute lymphocytic leukemia has resulted in the dominance of hematological
malignancies in the market
- Therapy for solid tumors is expected to emerge as the
lucrative source of revenue generation in the forthcoming years
- Rising research activities in CAR T-cell therapy for
solid tumors, particularly, for brain & central nervous system and
melanoma, is expected to benefit the key players
- North America led the global market in 2018 owing to the
presence of a large number of cancer centers engaging in research
activities. Moreover, U.S.-based pharma companies like Pfizer Inc. and
Celgene Corporation have shifted their focus from conventional drug
development to T-cell therapy space
- Asia Pacific is estimated to witness the fastest growth
with China at the forefront. China has surpassed the number of CAR T
clinical trials conducted in U.S. Moreover, Novartis is strategizing to
secure approval for Kymriah by China regulatory authorities in the
forthcoming years
- Gilead Sciences, Novartis AG, TCR2 Therapeutics Inc.,
Celgene Corporation, Sorrento Therapeutics, bluebird bio, and Fate
Therapeutics are some key players operating in the market. They engage in
mergers and acquisitions with therapy developers. Acquisition of Juno
Therapeutics by Celgene in January 2018 and Kite Pharma by Gilead in
August 2017 are some notable examples of acquisitions in this market
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment